Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
29 hedge funds and large institutions have $27.6M invested in Trillium Therapeutics Inc. in 2016 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 6 closing their positions.
0% more funds holding
Funds holding: 29 → 29 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
7% less capital invested
Capital invested by funds: $29.5M → $27.6M (-$1.93M)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NLVP
New Leaf Venture Partners
New York
|
+$839K |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$680K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$304K |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$154K |
| 5 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$152K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.45M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$546K |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$361K |
| 4 |
PA
Perceptive Advisors
New York
|
-$278K |
| 5 |
Renaissance Technologies
New York
|
-$236K |
TRIL Hedge Fund Activity: Q2 2016 in Review
29 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q2 2016, worth a combined $27.6M — down 6.5% from $29.5M a quarter earlier.
Fund positioning in TRIL was balanced in Q2 2016: 6 funds opened new positions, 6 closed out, 5 added to existing stakes and 8 trimmed.
The largest buyer was New Leaf Venture Partners, opening a new position worth an estimated $839K. The largest seller was Millennium Management, cutting an estimated $1.45M.
- 29 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $27.6M of Trillium Therapeutics Inc. stock for Q2 2016, down 6.5% quarter-over-quarter.
- 6 funds opened new Trillium Therapeutics Inc. positions in Q2 2016 and 6 closed out, a net change of 0 holders.
- The largest Trillium Therapeutics Inc. buyer in Q2 2016 was New Leaf Venture Partners, an estimated $839K added.
- The largest Trillium Therapeutics Inc. seller in Q2 2016 was Millennium Management, an estimated $1.45M sold.
Based on aggregated 13F filings for Q2 2016.